"A simple, blind, randomized, phase I / II trial to determine the safety and immunogenicity of a combination of AZD1222 and rAd26-S drugs, administered according to the heterologous prime-boost scheme, for the prevention of new coronavirus infection COVID-19 in adults," the table says.
It is specified that 150 patients will take part in the study.
It is scheduled to be completed on March 2, 2022.
In February, clinical trials of the combination vaccine Sputnik V and the British company AstraZeneca began.
Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), noted on the sidelines of the SPIEF that the "cocktail of vaccines" is a very relevant topic. According to him, they are at the heart of the effectiveness and fight against mutations.